Alterations of the axonal transport and microtubule network are potential causes of motor neurodegeneration in mice expressing a mutant form of the superoxide dismutase 1 (SOD1 G37R ) linked to amyotrophic lateral sclerosis (ALS). In the present study, we investigated the biology of microtubuleassociated proteins (MAPs), responsible for the formation and stabilization of microtubules, in SOD1 G37R mice. Our results
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the progressive loss of motor neurons leading to paralysis and death within 3-5 years (for review see Julien 2001) . Five to 10% of cases of ALS are familial and the others are believed to be sporadic. Mutations in the gene encoding superoxide dismutase 1 (SOD1) account for 20% of cases of familial ALS (Rosen 1993; Cudkowicz et al. 1997) .
The SOD1 protein is a cytosolic copper-and zinc-dependent enzyme which converts superoxide anions into hydrogen peroxide. Transgenic mice expressing mutant SOD1 develop the ALS phenotype through the gain of novel, cytotoxic activity, the nature of which remains unknown (Wong et al. 1995; Bruijn et al. 1997 Bruijn et al. , 1998 . Several primary mechanisms have been proposed to explain this cytotoxicity such as oxidative stress (Wiedau-Pazos et al. 1996) , glutamate-mediated excitotoxicity (Trotti et al. 1999) , apoptosis mediated by caspase activation (Li et al. 2000) , and deregulation of cyclindependent kinase 5 (Cdk5; Nguyen et al. 2001 ).
The most common pathological hallmark in both sporadic and SOD1-mediated ALS is the abnormal accumulation of cytoskeletal proteins such as neurofilaments, in the perikaryon or axon of spinal motor neurons (Hirano et al. 1984; Rouleau et al. 1996) . Such accumulation has also been observed in SOD1 mutant mice (Wong et al. 1995; Bruijn et al. 1997) . Furthermore, an accumulation of tubulin has been reported in the perikarya and/or proximal axonal segments of spinal motor neurons in SOD1 mutant mice (Williamson and Cleveland 1999) . These abnormalities are compatible with the slowing of the axonal transport detected in these mice (Williamson and Cleveland 1999) .
Of particular interest, are the aberrant modifications of microtubule-associated proteins (MAPs) in ALS patients and in mice expressing SOD1 mutant. Indeed, the abnormal hyperphosphorylation of tau is detected in SOD1 mutant mice 10-11 months old (Nguyen et al. 2001) and has been attributed to deregulation of Cdk5, a prominent kinase in the CNS (for a review see Dhavan and Tsai 2001) . Moreover, in dendrites, the expression levels of MAP2 decreased in patients with ALS (Kikuchi et al. 1999) . This decrease correlated with the degree of degeneration and with the clinical symptoms of limb weakness. Alternatively, the loss of the cytoskeleton within the dendrites of spinal motor neurons in ALS patients may constitute a mechanism of neuronal atrophy (Kiernan and Hudson 1993) .
It is, however, unclear whether alterations of the cytoskeleton occur at an early stage of the disease before initiation of neuronal death. In the present study, we examined the biology of axonal and dendritic MAPs in SOD1 G37R mice before and after neurodegeneration. Our results provide compelling evidence that the molecular integrity of the dendritic and the axonal microtubules is compromised months before the onset of symptoms in SOD1 G37R mice.
Materials and methods

Materials
The cocktail of protease inhibitors was purchased from Roche Diagnostics (Laval, Quebec, Canada). The Bio-Rad DC protein assay kit and the Bio-Rad protein assay kit based on the method of Bradford were purchased from Bio-Rad Laboratories (Hercules, CA, USA). The monoclonal anti-MAP2 (clone HM2), the anti-a-tubulin (clone DM1A), the anti-b-actin and Taxol were obtained 
Generation of SOD1 G37R mice
Inbred C57BL6 SOD1 G37R mice (line 29) were used in this study.
These mice have a life span of approximately 11-12 months (Nguyen et al. 2000 (Nguyen et al. , 2001 . The mouse genotypes were determined by Southern blotting of tail DNA. The use of animals and all surgical procedures described in this article were carried out according to The Guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care.
Preparation of total protein extracts
The mice were sacrificed by intraperitoneal injection of chloral hydrate. After dissection, the spinal cord samples were frozen immediately at ) 80°C. Total protein extracts were prepared by homogenization in sodium dodecyl sulfate (SDS) 0.5%, urea 8 M buffer to which a cocktail of protease inhibitors has been added prior to use. The homogenate is then centrifuged at 12 000 g for 10 min at 4°C and the pellet is discarded. The protein concentration was estimated using the Bio-Rad DC protein assay.
Immunoblotting and dot blotting
Proteins were fractionated on a 7.5% polyacrylamide gel and transferred on a nitrocellulose membrane for western blot analysis. For dot blotting, 30 lg of total protein were applied to a nitrocellulose membrane using a dot blot Manifold apparatus. The membrane was air dried for 20 min and was then incubated with the primary antibody for 60 min at room temperature. The membrane was then washed and incubated with the secondary antibody conjugated to horseradish peroxidase (HRP) and revealed by chemiluminescence. To quantify the protein level, the autoradiographic bands or dots were scanned and the digitized data were quantified using the program ImageQuant. Non-saturated blots were used for quatification and different exposure times insured consistency.
Taxol stabilized microtubule preparations
Spinal cord were dissected out and homogenized in a dounce homogenizer in 2 mL of taxol 20 lM/Saponin 0.01% PHEM extraction medium (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl 2 ) to which a cocktail of protease inhibitors was added prior to use (Black et al. 1986; Zhu et al. 1998) . The homogenates were incubated at room temperature for 8 min to solubilize unassembled tubulin and then centrifuged for 15 min at 29 957 g. The pellets were dissolved in 1% SDS-Tris buffer (50 mM Tris, pH 7.4) and the protein content was estimated using the Bio-Rad DC protein assay kit.
Preparation of membrane extracts
The spinal cord was homogenized in 10 volumes of 0.25 M sucrose dissolved in ice-cold 10 mM Tris-HCl buffer, pH 7.4 to which a cocktail of protease inhibitors was added prior to use. The homogenate was centrifuged at 1500 g for 15 min at 4°C to remove cell debris. The supernatant was then centrifuged at 105 000 g for 1 h at 4°C and the new supernatant was saved. This fraction was referred to as Ôsoluble cytosolÕ. The remaining pellet was resuspended in the above sucrose-Tris buffer and was referred to as Ômembrane fractionÕ. The protein content of the different fractions was determined using the Bio-Rad protein assay kit based on the method of Bradford.
Results
Decreased levels of MAPs before disease onset in the spinal cord of SOD1 G37R mice To investigate the contribution of MAPs at an early stage of neurodegeneration in SOD1 G37R mice, we examined the protein levels of dendritic and axonal microtubule-associated proteins in SOD1 G37R mice 5 months before the onset of clinical symptoms. Using antibodies that recognize the dendritic MAP2 (HM2), the axonal tau (46.1) and MAP1A (MAB362), a MAP present in both compartments, we determined by western blotting or dot blotting the protein levels of these MAPs in total spinal cord extracts from normal mice (WT) and SOD1 G37R mice that were 5.5 months old. HM2, 46.1 and MAB362 are phospho-independent antibodies. Quantitative analysis was performed using the ImageQuant program. As shown in Figs 1(a and b), the protein levels of MAP2, tau isoforms and MAP1A do not change with aging in the spinal cord of normal mice but decrease dramatically in 5.5-month-old SOD1 G37R mice following a distinct pattern: MAP1A levels are always altered, followed by MAP2 and finally by the tau isoforms. Levels of tau 52-55 kDa species are always the less affected. Figure 1 (a) shows an example of a 5.5-month-old SOD1 G37R mouse exhibiting a significant decrease in protein levels for all MAPs. The quantitative analyses revealed that the levels of MAP1A, MAP2, tau 100 kDa species, and tau 68 kDa species decrease significantly in 5.5-month-old SOD1 G37R mice as compared with normal mice with remaining levels of 60.35% ± 14.52, 41.99% ± 14.19, 55.1% ± 19.32, and 46.44% ± 15.53, respectively (Fig. 1b) . Surprisingly, the level of tau 52-55 kDa species decreases importantly only in three of the six 5.5-month-old SOD1 G37R mice examined and thus the average percentage compared with normal mice is not significant (70.17% ± 19.31). Fig. 1 The protein levels of microtubule-associated proteins were examined in normal mice and in SOD1 G37R mice. n indicates the number of animals. Quantitative analysis was performed using densitometry. The results are presented as average ± SEM. The statistical significance was determined using the t-test. The asterisk indicates statistical difference (*p < 0.05). (a) Western blots of total spinal cord extracts from normal mice and from SOD1 G37R mice were revealed using the HM2 antibody (anti-MAP2), the 46.1 (tau isoforms), and an anti-MAP1A (MAB362). A total of 30 lg of protein were loaded per lane. The protein level is similar in the different lanes as indicated by actin staining (c isoform). MAP1A was quantified using either western blot or dot blot technique. A western blot of MAP1A shows the specifity of the antibody MAB362. (b) The protein levels of MAPs do not change with aging in the spinal cord of normal mice. In the 5.5-month-old SOD1 G37R mice, a significant decrease of the level of MAP1A, MAP2, tau 100 kDa, and tau 68 kDa species is noted. An alteration of the protein level of tau 52-55 kDa species occurs in 10-11-month-old SOD1 G37R mice.
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We also examined the change in the protein levels of MAP1A, MAP2 and tau isoforms in 10-11-month-old SOD1 G37R mice. As shown in Figs 1(a and b) , the protein levels of all MAPs have decreased significantly at this stage as compared with normal mice. The remaining levels for MAP1A, MAP2, tau 100 kDa species, tau 68 kDa species, and tau 52-55 kDa species are 50.47% ± 13.72, 1.62% ± 0.46, 12.14% ± 3.03, 13.88% ± 4.80, and 50.11% ± 10.78, respectively. Taken together, the above results indicate that the protein levels of both axonal and dendritic MAPs decrease in the spinal cord of SOD1 G37R mice. This decrease occurs before disease onset for MAP1A, MAP2, tau 100 kDa, and tau 68 kDa species, whereas an important decrease of the protein level of tau 52-55 kDa species is noted mostly with the manifestation of clinical symptoms and paralysis. In contrast to other MAPs, the level of MAP1A decreases in 5.5-month-old SOD1 G37R mice and then remains at the same level at later stages of the disease.
To confirm that the decrease of the protein levels of MAPs is specific to the neurodegenerative processes occurring in the spinal cord, we examined the levels of these proteins in the brain of SOD1 G37R mice, a CNS organ spared by the mutant SOD1 toxicity (Wong et al. 1995; Nguyen M. D. et al., personal communication) . As shown in Figs 2(a and b) , the protein levels of MAP2, MAP1A, and of tau species do not change significantly with aging in normal brain even though the protein level of MAP1A appears to be decreased in two of the four 10-month-old SOD1 G37R mice examined. No significant decrease of the protein levels of MAPs was detected either in the brain of 6.5-month-old SOD1 G37R mice or in 10-month-old SOD1 G37R mice (Figs 2a and b) . However, a noticeable decrease in levels of MAP2 was detected in two of the four 10-month-old SOD1 G37R mice examined. Collectively, the above results demonstrate that the decrease of MAPs precedes neurodegeneration in the spinal cord of SOD1 G37R mice.
No change of the protein levels of tubulin, actin or neurofilaments before disease onset in SOD1 G37R mice We next examined the change in the levels of tubulin, actin, and neurofilaments in SOD1 G37R mice 5.5 months before disease onset. Using antibodies that recognize tubulin (DM1A for the a isoform), actin (b and c isoforms), and neurofilament subunits (RT-97 for NF-H, NN-18 for NF-M, and NR4 for NF-L), we have determined by western blotting the levels of these proteins in total spinal cord extracts from normal mice and SOD1 G37R mice at 5.5 months and 10-11 months old. At the exception of RT-97, all of the antibodies used are phospho-independent. Quantitative analysis was performed as described in the previous section. There is no significant decrease in the levels of a-tubulin, b-actin, c-actin, NF-H, NF-M or NF-L in 5.5-month-old SOD1 G37R mice (Figs 3a and b) . At 10-11 months, as illustrated in Figs 3(a and b) , the levels of a-tubulin, c-actin, and NF-L are not significantly altered. However, the level of b-actin diminishes in these mice with a remaining level of 31.28% ± 17.74. Furthermore, the levels of NF-H and NF-M also decrease at this stage with remaining levels of 76.82% ± 1.44 and 70.42% ± 6.80, respectively. Collectively, our results reveal that the levels of tubulin, actin, and neurofilaments do not decrease before disease onset in SOD1 G37R mice. However, the levels of b-actin, NF-H, and NF-M decrease in 10-11-month old SOD1 G37R mice when the clinical symptoms begin to appear. Any decrease of the protein level in end-stage mutant mice could be due to the extensive neuronal loss observed at this age. Decreased binding affinities of MAPs to the cytoskeleton before disease onset in SOD1 G37R mice To further analyse the alterations of MAPS in ALS mice, we determined their binding affinities to the cytoskeleton. We prepared taxol-stabilized cytoskeletal fractions from the spinal cord of normal mice and 5.5-month-old SOD1 G37R mice and compared their content in MAPs. As previously reported, this preparation contains microtubules, neurofilament subunits, and actin (Black et al. 1986; Zhu et al. 1998) . The Ôinsoluble cytoskeletal fractionÕ and the Ôsoluble cytoskeletal fractionÕ were prepared as described in methods and were analysed by western blotting for their content in tubulin, MAP1A, MAP2, and tau isoforms. Quantitative analysis was performed as described above. The proportion of insoluble cytoskeletal fraction was determined for each MAP. Because taxol is used in the extraction buffer, tubulin is found almost exclusively in the insoluble cytoskeletal fractions in normal mice and 5.5-month-old SOD1 G37R mice (Fig. 4a) . In the control mouse, the amount of MAPs in the insoluble fraction was higher than in the soluble fraction, whereas in mutant mice, the opposite was observed. The proportion of insoluble MAP1A in the normal mouse was 61.54%. This number decreased to an average of 32.32% in the three SOD1 G37R mice tested. Furthermore, the proportion of insoluble MAP2 was 56.71% in the normal mouse. This number diminished to 20.84% in the three mutant mice examined. Moreover, we verified the proportion of insoluble tau isoforms in these mice with the phosphorylationindependent antibody 46.1. In the normal mouse, the proportion of insoluble tau 100 kDa, tau 68 kDa, and tau 52-55 kDa species was 35.88%, 40.93%, and 66.9%, respectively. In the three mutant mice, this ratio decreased to 26.58%, 28.8%, and 26.66%, respectively. Figure 4(b) shows the relative proportion of insoluble MAPs in 5.5-month-old SOD1 G37R mice compared with normal mice. Our observations indicate that the binding affinities of MAP1A, MAP2, and tau isoforms to the cytoskeleton decrease in SOD1 G37R mice as early as 5 months before disease onset. Previous studies reported a change in the phosphorylation state of tau 52-55 kDa species in 10-11-month-old SOD1 G37R mice at the epitopes recognized by the AT-8 and the PHF-1 antibodies (Ser199/202, Thr205 for AT8 and Ser 396/404 for PHF-1; Nguyen et al. 2001) . To determine whether a change in the phosphorylation state of tau is associated with decreasing its binding affinity to the cytoskeleton, the insoluble/soluble fractions were stained with the AT8 and the PHF-1 antibodies. As shown in Fig. 4(a) , there was an increase of the phosphorylation state of tau 52-55 kDa species in the three SOD1 mutants tested. Interestingly, this increase occurred in the soluble fraction, suggesting that a change in the phosphorylation state of tau might be responsible for decreasing its binding affinity to the cytoskeleton. No change in the phosphorylation state of tau 100 kDa and tau 68 kDa species was observed at the epitopes recognized by the AT8 and the PHF-1 antibodies. Interestingly, the binding affinity of tau 52-55 kDa to the cytoskeleton is more severely affected than that of tau 100 and tau 68 kDa species. We also tested Tau-1 antibody that recognizes a dephosphorylated epitope of tau at amino acids 191-224. No change in the staining of tau 100 kDa, tau 68 kDa or tau 52-55 kDa species was detected with this antibody (Fig. 4a) .
Finally, to test whether the phosphorylation state of MAP2 was affected in SOD1 G37R mice, we used the phosphodependent antibody AP18 that recognizes residue Ser136 located in the projection domain of MAP2. This site is highly phosphorylated during dendritic outgrowth and plasticity (Riederer 1992; Riederer et al. 1995) . In the mutant mice examined, staining with the AP18 antibody was similar to that detected with the non-phosphorylation-dependent (a) (b) Fig. 3 The protein levels of tubulin, actin, and neurofilaments were examined in SOD1 G37R mice. n indicates the number of animals.
Quantitative analysis was performed using densitometry. The results are presented as average ± SEM. The statistical significance was determined using the t-test. The asterisk indicates statistical difference (*p < 0.05). (a) Western blots of total spinal cord extracts from SOD1 G37R mice and from normal mice were revealed using the anti- compared with normal mice. However, the protein levels of actin (b-isoform), NF-H, and NF-M decrease significantly in 10-11-monthold SOD1 G37R mice (h).
antibody HM2 (Fig. 4a) . Thus, we can conclude that the phosphorylation state of MAP2 at residue Ser136 does not change in SOD1 G37R mice. However, this does not rule out the possibility of alteration in the phosphorylation of MAP2 in SOD1 G37R mice.
Alteration of the membrane proportion of MAP2 in SOD1 G37R mice Previous studies reported that MAPs interact with membranous components. As such, tau is found at the plasma membrane in neuronal cell lines (Maas et al. 2000) .
Furthermore, the interaction of MAP2 with plasma membrane-associated proteins as well as integral plasma membrane proteins has also been observed (Davare et al. 1999; Lim and Halpain 2000) . Moreover, an interaction of both MAP2 and tau with mitochondria has been reported (Jancsik et al. 1989; Linden et al. 1989; Jung et al. 1993) . In the present study, a Ôtotal membrane fractionÕ and a Ôsoluble cytosol fractionÕ were prepared from the spinal cord of normal mice and SOD1 G37R mice as described in Methods (Fig. 5a ). The fractions were analyzed by western blotting to determine their content with the plasma membrane marker protein Na-K ATPase and with the mitochondrial marker protein VDAC. As shown in Fig. 5(b) , the total membrane fractions were enriched with plasma membranes and with mitochondria. These fractions were also analysed to determine their content with MAP1A, MAP2, and tau isoforms. Quantitative analysis was performed as described above. The membrane proportion was calculated for each protein. Four control mice, four 5.5-month-old SOD1 G37R mice, and four 10-11-month-old SOD1 G37R mice were examined (Fig. 5c) . The average membrane proportion of MAP2 in normal mice was 5.37% ± 3.3. This proportion increased in two of the four 5.5-month-old SOD1 G37R mice examined and then increased significantly to become an average of 43.65% ± 2.41 in the four 10-11-month-old SOD1 G37R mice examined. From these observations, one can conclude that the alteration of the membrane proportion of MAP2 correlates with neurodegeneration in SOD1 G37R mice. The average membrane proportions of tau 100 kDa and tau 68 kDa species in normal mice were 5.39% ± 3.57 and 20.84% ± 4.8, respectively. These proportions did not change significantly in 5.5-months-old and in 10-11-month-old SOD1 mutant mice. The average membrane proportion of tau 52-55 kDa species was 62.78% ± 2.67 in normal mice. This proportion decreased significantly in 5.5-month-old Fig. 4 Taxol-stabilized cytoskeletal fractions were prepared from spinal cord of normal mice and 5.5-month-old SOD1 G37R mice as described in Materials and methods. (a) Western blots of insoluble and soluble cytoskeletal fractions were revealed using the anti-a-tubulin, the HM2 antibody (anti-MAP2), the 46.1 (tau isoforms), and an anti-MAP1A. The fractions were also stained with the phospho-dependent anti-tau antibodies AT8 and PHF-1 as well as the dephosphorylation dependent antibody Tau-1. A total of 30 lg of protein were loaded per lane. Densitometric analysis was performed as described in Materials and methods. The proportion of insoluble MAP1A, MAP2, and tau isoforms decreases in 5.5-month-old SOD1 G37R mice, indicating a decrease in the binding affinities of MAPs to the cytoskeleton. Furthermore, there is an increase of the phosphorylation state of the soluble tau 52-55 kDa species at the epitopes recognized by the AT8 and the PHF-1 antibodies. Membranes were also revealed with the phospho-dependent anti-MAP2 antibody AP18 that recognizes residue Ser136 located in the projection domain of MAP2. (b) The relative decrease of the proportion of insoluble MAPs in 5.5-month-old SOD1 G37R mice is presented compared with normal mice.
SOD1
G37R mice to become 52.44% ± 3.08. However, this decrease was observed in only two of the four 10-11-monthold SOD1 G37R mice examined. Thus, this lack of consistency did not allow us to correlate the alteration of the membrane proportion of tau 52-55 kDa species with neurodegeneration. The average membrane proportion of MAP1A in normal mice was 29.03% ± 6.9. This number did not change significantly in 5.5-month-old or 10-11-month-old SOD1 G37R mice.
Discussion
In the present study, we report decreased protein levels of MAPs before disease onset in SOD1 G37R mice. The fact that this decrease was only noted in the spinal cord where neuronal cell death mainly occurs indicates that it could contribute to cell dysfunction leading to neurodegeneration in SOD1 mutant mice. In different experimental contexts, a decrease of MAP protein levels was induced by excitotoxicity, traumatic brain injury, focal ischemia, and oxidative stress (Irving et al. 1996; Posmantur et al. 1996; Arias et al. 1997) . In SOD1 G37R mutants, glutamate-induced excitotoxicity is one plausible mechanism contributing to neuronal cell death. This excitotoxicity would be mainly caused by a reduction of the astroglial glutamate transporter EAAT2 (Rothstein et al. 1995) . The involvement of other non-neuronal cells, possibly glial cells, in ALS pathogenesis is supported by a recent study reporting that the expression of high levels of human SOD1 G37R mutant specifically in large motor neurons of the spinal cord of transgenic animals does not cause neurodegeneration (Pramatarova et al. 2001) . According to this hypothesis, the alterations of the protein levels of MAPs in SOD1 G37R mice might be secondary to a glutamate-induced neuronal excitotoxicity. In support of this idea, one study reported that glutamate receptor antagonists inhibit calpainmediated proteolysis of cytoskeletal proteins such as MAP2 and tau, known substrates for calpains (Johnson et al. 1989; Fischer et al. 1991; Minger et al. 1998) . Calpain activity was reported to be deregulated in neurodegenerative diseases and could result from an altered calcium homeostasis due in part to an increase of extracellular glutamate, mitochondrial defects, and oxidative stress (Saito et al. 1993) . Therefore, the early decrease of MAPs reported in the present study might indicate that calpain deregulation is one of the events leading to neuronal cell dysfunction and death in SOD1 G37R mice.
Interestingly, the protein level of MAP1A decreases as early as 5 months before disease onset in SOD1 G37R mice and does not diminish significantly afterwards even when neuronal loss is apparent. This might indicate an increase of the level of MAP1A during neurodegeneration in SOD1 G37R mice as a compensatory effect following the decrease of MAP2 and tau. Indeed, in tau knockout mice, an increase of MAP1A was reported (Harada et al. 1994) . In the case of tau proteins, the level of tau 52-55 kDa species is altered mostly when neurodegeneration is apparent in SOD1 G37R mice. This is the only tau isoform to present a change in its phosphorylation state at the epitopes recognized by the antibodies AT-8 and PHF-1. One explanation is that phosphorylated tau is more resistant to proteolysis as reported in previous studies (Litersky and Johnson 1995) . This selectivity towards tau 52-55 kDa species might also indicate that distinct signalling pathways regulate different tau isoforms. Distinct regulation of tau isoforms is observed in several ÔtauopathiesÕ where a specific set of pathological tau proteins exhibit a typical biochemical pattern and different laminar and regional distribution (for review see Buee et al. 2000) . Notably, the protein levels of other cytoskeletal proteins such as b-actin and the neurofilament subunits NF-H and NF-M decrease significantly when the clinical symptoms begin to appear in SOD1 G37R mice. b-actin is enriched in structures having high capacity of remodeling in mature neurons such as dendritic spines in contrary to c-actin that is found in dendrites, axons, and in the cell body (Micheva et al. 1998) . The decrease of b-actin might indicate that dendritic spines are affected severely with onset of symptoms in SOD1 G37R mice. In the case of neurofilament subunits, a previous study reported that the level of NF-L mRNA decreases in ALS cases, whereas that of NF-H and NF-M remains unchanged (Wong et al. 2000) . If subtle changes of the neurofilament protein levels occur before disease onset, preparation of a total spinal cord extract may not allow us to detect them.
The implication of the decrease of MAPs on microtubule structure and function remains elusive. However, recent studies demonstrated that a complete suppression of either tau or MAP2 expression does not lead to an important decrease of microtubule density in knockout mice (Harada et al. 1994 (Harada et al. , 2002 . Therefore, a decrease of the protein levels of these MAPs before disease onset in SOD1 G37R mice does not necessarily imply a decrease of the microtubule density in affected dendrites and axons. For instance, the apparent increase of the protein level of MAP1A observed in SOD1 G37R mice might compensate for the described loss of MAP2 and tau species as previously reported.
Remarkably, a decrease in the binding affinities of MAP1A, MAP2, and tau isoforms to the cytoskeleton is observed as early as 5 months before disease onset in SOD1 G37R mice. MAP1A, MAP2, and tau are phosphoproteins and their interaction with microtubules depends on their phosphorylation state (Buee et al. 2000; Sanchez et al. 2000) . Our present results reveal an increase in the phosphorylation state of the soluble tau 52-55 kDa at the epitopes recognized by the antibodies AT-8 and PHF-1 in 5.5-month-old SOD1 G37R mice. Thus, one explanation of the decrease of the binding affinities of MAPs to microtubules would be a deregulation of the activity of one or many kinases in SOD1 G37R mice. Deregulation of kinases has been linked to ALS (Wagey and Krieger 1998) . For instance, Cdk5, associated with oxidative stress in degenerating motor neurons in ALS patients, is abnormally hyperactivated in the spinal cord of 8-12-month-old SOD1 G37R mice (Nguyen et al. 2001) . This deregulation of Cdk5 in these mice was associated with the hyperphosphorylation of tau at sites recognized by the antibodies PHF-1 and AT-8. Moreover, activation of Cdk5 is known to abolish the binding of tau to microtubules (Wada et al. 1998; Patrick et al. 1999) . The activity of other kinases such as the Ca( 2+ )-phospholipiddependent-protein kinase C (PKC) has been also reported to be abnormally amplified in ALS patients (Lanius et al. 1995; Krieger et al. 1996) and tau is a substrate for PKC via the MAP kinase pathway (Ekinci and Shea 1999) . PKC also phosphorylates MAP2 (Ser1703, Ser1711, and Ser1728) and abolishes its association with microtubules (Hoshi et al. 1988) . Furthermore, inhibition of Janus kinase-3 (JAK3) has been shown to increase survival in mice expressing mutant SOD1 (Trieu et al. 2000) although it is still unknown whether JAK3 phosphorylates MAPs. Our observation of hyperphosphorylation of tau 5 months before disease onset indicates that deregulation of kinases and/or balance in phosphatases/kinases activity occurs early in the process of neurodegeneration in mutant SOD1 mice.
Another alteration observed in SOD1 G37R mice is a significant increase of the membrane proportion of MAP2 in two of the 5.5-month-old SOD1 G37R mice examined and in the four 10-11-month-old SOD1 G37R mice used in this study. MAP2 can interact with plasma membrane-associated proteins such as Src and Grb2 as well as integral plasma membrane proteins such as the class C L-type calcium channel (Davare et al. 1999; Lim and Halpain 2000) . The interaction of MAP2 with Src and Grb2 is phosphodependent (Hoshi et al. 1988; Lim and Halpain 2000; Ozer and Halpain 2000) . Thus, one explanation of the altered distribution of MAP2 in SOD1 G37R mice could be a change in the phosphorylation state of the protein affecting its interaction with membranous components. Another possibility is that MAP2 has an altered conformational state induced by unknown mechanisms in SOD1 mutant mice and thus behaves differently in the experimental conditions used to prepare membrane and cytosolic fractions.
In summary, our study shows that the molecular integrity of both dendritic and axonal microtubules is altered before onset of symptoms in SOD1 G37R mice. Our results are compatible with a previous study which reported reduced transport of selective cargoes of the slow axonal transport before disease onset in SOD1 mutant mice indicating that microtubule function is affected (Williamson and Cleveland 1999) . Thus, microtubules appear to be an early target in the neurodegeneration process in SOD1 mutant mice. The characterization of these early targets will help to elaborate preventive therapeutic strategies.
